Heron Therapeutics (HRTX) Short-term Investments (2015 - 2026)

Heron Therapeutics has reported Short-term Investments for 12 years, with the latest figure at $18.7 million in Q1 2026.

• For the quarter ending Q1 2026, Short-term Investments fell 40.57% year-over-year to $18.7 million; the trailing twelve-month figure through Mar 2026 stood at $18.7 million (down 40.57% YoY), and the FY2025 full-year result was $18.0 million, down 46.29% from the prior year.
• Short-term Investments for Q1 2026 stood at $18.7 million, up from $18.0 million in the prior quarter.
• The five-year high for Short-term Investments was $71.3 million in Q3 2022, with the low at $12.4 million in Q3 2025.
• Historically, Short-term Investments has averaged $38.9 million across 5 years, with a median of $34.9 million in 2022.
• Annual changes were most pronounced in 2024 — Short-term Investments surged 147.5% — and 2025, when it plunged 72.49%.
• Heron Therapeutics' Short-term Investments stood at $69.5 million in 2022, then decreased by 25.55% to $51.7 million in 2023, then plunged by 35.28% to $33.5 million in 2024, then sank by 46.29% to $18.0 million in 2025, then climbed by 3.8% to $18.7 million in 2026.
• The last three Short-term Investments figures came in at $18.7 million (Q1 2026), $18.0 million (Q4 2025), and $12.4 million (Q3 2025), per Business Quant data.